Haemonetics' (HAE) "Strong-Buy" Rating Reaffirmed at Raymond James

Haemonetics (NYSE:HAE - Get Free Report)'s stock had its "strong-buy" rating reiterated by research analysts at Raymond James in a research note issued to investors on Friday,Benzinga reports. They presently have a $115.00 price objective on the medical instruments supplier's stock, down from their previous price objective of $120.00. Raymond James' price objective points to a potential upside of 85.20% from the company's current price.

A number of other analysts have also weighed in on the stock. JMP Securities dropped their target price on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a report on Friday. Barrington Research lowered their price objective on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a report on Friday. Needham & Company LLC lowered their price objective on shares of Haemonetics from $112.00 to $108.00 and set a "buy" rating for the company in a report on Friday. JPMorgan Chase & Co. initiated coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an "overweight" rating and a $116.00 price objective for the company. Finally, Bank of America lowered shares of Haemonetics from a "neutral" rating to an "underperform" rating and lowered their price objective for the stock from $95.00 to $68.00 in a report on Friday. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $101.67.

Haemonetics Price Performance

HAE traded up $1.46 during trading on Friday, reaching $62.10. The stock had a trading volume of 1,027,005 shares, compared to its average volume of 995,138. The stock has a market cap of $3.12 billion, a PE ratio of 24.45, a PEG ratio of 0.98 and a beta of 0.39. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.09 and a current ratio of 3.97. Haemonetics has a one year low of $58.80 and a one year high of $97.97. The business has a 50-day moving average of $75.84 and a 200-day moving average of $78.01.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, equities research analysts anticipate that Haemonetics will post 4.59 EPS for the current fiscal year.

Institutional Trading of Haemonetics

Several hedge funds have recently bought and sold shares of HAE. Whittier Trust Co. bought a new stake in shares of Haemonetics in the 4th quarter worth about $62,000. Nisa Investment Advisors LLC increased its holdings in shares of Haemonetics by 124.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 632 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares during the last quarter. AlphaQuest LLC grew its holdings in Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after purchasing an additional 1,826 shares during the last quarter. Finally, KBC Group NV grew its holdings in Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after purchasing an additional 712 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.